Indian High Court in Chennai Delivers a Decisive Product Patent Victory to Kibow Biotech Inc Specializing in Kidney Health Supplement "Renadyl™" - the Flagship Product for its "Enteric Dialysis®" Platform Technology

NEWTOWN SQUARE, Pa., Feb. 22, 2019 /PRNewswire/ -- Kibow Biotech Inc is pleased to announce that it has achieved a significant victory with its India patent in a lawsuit brought by La Renon an Ahmedabad based company.  [Patent No. 351/MUMNP/2006, 224100 "Compositions for Augmenting Kidney Function" Patent No. 224100, - issued September 29, 2008]. La Renon had challenged the validity of Kibow's patent before India's specialized IP tribunal, the Intellectual Property Appellate Board (IPAB) in 2013. The IPAB dismissed the challenge and upheld Kibow's patent. The Madras High Court has now validated the IPAB order and effectively upheld Kibow's patent once again.

Kibow recently initiated collaboration in Nov 2017 with Centaur Pharmaceuticals, Mumbai, India. - https://www.centaurpharma.com/ Centaur Pharmaceuticals has exclusive rights for importing, blister packaging, marketing, distribution and sale of Renadyl™ throughout India.  Kibow has also obtained the same patent and several more totaling thus far 35 patents in Australia, Canada, China, Japan, Korea, European Union and USA.

Kibow Biotech Inc is a privately held small biotech firm established in the year 1997 with the concept of Substituting the failing Kidney function by the Bowel – Hence the name KIBOW and its platform technology is known as "Enteric Dialysis®" with its patented and proprietary Probiotics/Prebiotics flagship product "Renadyl™" for human applications and "Azodyl®" for cats and dogs (Licensed to Vetoquinol, a European publically traded veterinary business firm).

Currently Renadyl™ https://renadyl.com/  is marketed and sold via its own online web site and on Amazon as a kidney health dietary supplement.  However, the company has performed extensive pharma like validation, and all its scientific abstracts and peer-reviewed publications can be found in the company's website educational resources https://kibowbiotech.com/rd/ and https://kibowbiotech.com/journal-publications/.

A new program by Human Health Services (HHS) and American Society of Nephrology (ASN) to accelerate innovation in Kidney disease has taken the front stage and recently launched as KidneyX program- https://www.hhs.gov/cto/initiatives/kidneyx/index.html.  Kibow Biotech Inc with its "Enteric Dialysis ®" project proposal certainly hopes to be a winner in this KidneyX prize competition. As a potential winner in this competition, Kibow hopes to garner greater investment/collaboration interest as a pioneer in modulation of "Gut Microbiome" in renal failure population and thus provide better outcome with improved Quality Of Life to both dialysis and pre-dialysis (CKD III/IV) patients worldwide. The company is also exploring to transition its dietary product formulation to a Live Bio-Therapeutic (LBT) drug classification.  This will help to qualify for medical reimbursement from both private insurance firms and federal governmental sources. Kibow has also formulated and validated with its recent rat animal model trials, a Pro/Prebiotic patented product towards Gout/Hyperuricemia applications and intends to develop this also as LBT. All needed protocols for human clinical trials will be made, adhered and conducted as mandated by Center for Biological Evaluation Research (CBER)/US FDA regulatory pathways.

Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the Renadyl™, and Gout products as drug candidates with all needed US FDA mandated clinical trials, and the possibility of its approval as a drug in some other countries according to respective governmental authorities. 

About "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.

Kidney health supplement with a pharma-like validation: Kibow Biotech is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment nor a therapy. The dietary supplement formulation of Renadyl™ is not meant to cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors. These include but are not limited to the possibility that Renadyl™ may not reduce levels of uremic toxins in each and every individual, due to differences that exist between individuals that cannot be controlled such as genetics and lifestyle factors, as well as environmental factors that would include proper storage of the product and conditions of transport of the product in the chain of commerce. Other factors that could cause or contribute to differences in actual results include, but are not limited to: whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Investor & Media Contact:
Terrence O. Tormey - CEO
(610) 353-5130
[email protected]

SOURCE Kibow Biotech, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED